Journal of Pharmacy Practice and Research最新文献

{"title":"Fred J Boyd 2023 oration","authors":"M. K. Dunkley","doi":"10.1002/jppr.1899","DOIUrl":"https://doi.org/10.1002/jppr.1899","url":null,"abstract":"","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"31 39","pages":""},"PeriodicalIF":2.1,"publicationDate":"2023-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138965934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimation of kidney function for medication dosing in adult patients with chronic kidney disease: a practice update","authors":"Sanja Mirkov BPharm, PGDipPH,&nbsp;Carla Scuderi MClinPharm, BPharm,&nbsp;Jess Lloyd BPharm, GradDipClinPharm,,&nbsp;John Coutsouvelis PhD, MClinPharm, BPharm, FSHP,&nbsp;Shaun O'Connor BPharm, MSHP,&nbsp;Simon Potts BPharm, BSc (Hons),&nbsp;Suzanne Newman BPharm, GradDipHospPharm,&nbsp;Jason Roberts PhD, BPharm (Hons), BAppSc, FSHP, FISAC, FAHMS","doi":"10.1002/jppr.1884","DOIUrl":"10.1002/jppr.1884","url":null,"abstract":"<p>Chronic kidney disease (CKD) is a major health concern with a growing disease burden and inequalities in access to treatments. Glomerular filtration rate (GFR) is accepted as the best overall measure of kidney function and is considered the most important measure for medications cleared by the kidneys. In clinical practice, equations that estimate GFR using validated prediction equations are routinely used. This practice update was developed by a Working Group comprising clinical pharmacists representing the Society of Hospital Pharmacists of Australia (SHPA) Specialty Practice streams of Nephrology, Oncology and haematology, Critical care and Infectious diseases. It is intended to provide practical recommendations for clinical pharmacists who use equations to estimate GFR for medication dosing decisions. The limitations of the various equations in use — such as the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), the Cockcroft–Gault equation and Modification of Diet in Renal Disease — are summarised and compared to direct measures of kidney function using exogenous markers. The CKD-EPI equation is recommended to be used routinely as a primary measure of kidney function. Dose adjustments should also consider medication-specific, patient-related, and disease-related characteristics. Kidney function and the response to therapy should be continuously assessed by monitoring the signs, symptoms and disease outcomes, the emergence of adverse reactions or medication-induced disorders and use therapeutic drug monitoring (if available) to adjust doses accordingly.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"54 1","pages":"94-106"},"PeriodicalIF":2.1,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1884","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136282180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication error reporting attitudes and practices in a regional Australian hospital: a qualitative study","authors":"Shady Abdelmaksoud BPharm, MClinPharm,&nbsp;Mohammed S. Salahudeen BPharm, PharmD, PhD, FHEA,&nbsp;Colin M. Curtain BPharm, GradDipComp, PhD","doi":"10.1002/jppr.1887","DOIUrl":"10.1002/jppr.1887","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Medication errors are events that may cause or lead to inappropriate medication use or patient harm. Australians living outside metropolitan areas have poorer health outcomes than those living in urban areas. Medication error reporting (MER) practices vary due to the attitude of healthcare professionals (HCPs). MER can improve patient safety in community and hospital settings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To explore HCPs' attitudes, practices, and recommendations towards MER in a regional hospital setting in Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Semistructured interviews were employed to identify the attitudes, practices, and recommendations of HCPs for the best utilisation of medication error reports. The study recruited HCPs (nurses, pharmacists, and doctors) working in all clinical areas from November 2021–February 2022. Interviews were recorded and transcribed via thematic analysis. Ethics approval was obtained from the Goulburn Valley Health (GVH) Human Research Ethics Committee (Reference no: GVH 35/21). Informed consent was obtained from participants via an information sheet and completion of a written consent form.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Interviews with twelve HCPs elucidated four themes: barriers and enablers to reporting, and perceived benefits and recommendations for medication error reports. There was good understanding among regional HCPs about the benefits of MER. Attitudes and practices varied, with nurses reporting more medication errors than doctors, and pharmacists being concerned about the impact of reporting on interprofessional relations. Their recommendations involved standardising medication error definition and improving electronic system education.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Despite HCPs' understanding of the role of MER, their practices varied. We recommend improved protected time for learning, training with the incident reporting software, education about medication errors, and formalisation of test feedback to clinicians. The implementation of workplace cultural practice changes to improve organisational systems and enhance error reporting without fear of repercussions, and the adoption of additional solutions such as electronic prescribing are also encouraged.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"54 1","pages":"41-47"},"PeriodicalIF":2.1,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1887","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135186215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of extrapyramidal side effects due to possible paliperidone: voriconazole interaction","authors":"Louise Beilby BPharm, GradCertPharmPrac,&nbsp;Lucy Arno BPharm (Hons), MHA","doi":"10.1002/jppr.1892","DOIUrl":"10.1002/jppr.1892","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>It is thought that paliperidone, an active metabolite of risperidone, has limited potential for pharmacokinetic drug–drug interactions (DDIs) due to minimal metabolism by cytochrome P450 3A4 (CYP3A4) and cytochrome P450 2D6 (CYP2D6). However, DDIs have been reported and include a theoretical interaction between paliperidone and voriconazole based on interactions between risperidone and strong CYP3A4 inhibitor azoles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To describe the first recorded DDI between paliperidone and voriconazole leading to extrapyramidal side effects (EPSEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Clinical details</h3>\u0000 \u0000 <p>A 34-year-old male presented with febrile neutropenia presumed due to clozapine. Clozapine was ceased and paliperidone commenced with voriconazole added to the patient's empiric piperacillin/tazobactam therapy due to a suspected fungal infection. Two days after starting voriconazole, the patient developed hypertonia and hyperreflexia in all limbs, thought most likely to be antipsychotic induced EPSEs. Paliperidone was withheld and EPSEs resolved.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Outcomes</h3>\u0000 \u0000 <p>The patient had previously tolerated long-term paliperidone at higher doses, prior to transitioning to clozapine. The development of EPSEs occurred two days post azole initiation, indicating a probable paliperidone adverse drug reaction (ADR) due to strong CYP3A4 inhibition by voriconazole. This case appears to be the first documented report of this previous theoretical DDI in practice. Further studies, including therapeutic drug monitoring, are required to confirm findings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Paliperidone may be affected by pharmacokinetic drug–drug interactions and patients should be monitored for ADRs when CYP3A4 inhibitors are concomitantly administered.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"54 1","pages":"70-73"},"PeriodicalIF":2.1,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1892","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135186209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists in Australian general practice: Discussion of the findings of an evaluation from 2016 to 2021","authors":"Louise S. Deeks BSc (Hons), PGDip, PGCert,&nbsp;Mark Naunton BPharm (Hons), PhD,&nbsp;Gregory M. Peterson BPharm (Hons), MBA, PhD,&nbsp;Thilini Sudeshika BPharm (Hons), PGDipToxicology, MPhil,&nbsp;Christopher Freeman BPharm, GDipClinPharm, PhD,&nbsp;Ravi Sharma MPharm (Hons), MSc, PGCert,&nbsp;Stacy Leavens BA, MA,&nbsp;Sam Kosari BPharm (Hons), PhD","doi":"10.1002/jppr.1878","DOIUrl":"https://doi.org/10.1002/jppr.1878","url":null,"abstract":"<p>Pharmacists embedded in general practice can improve medicines optimisation and patient safety, but Australia has been slower to adopt and fund this model than other comparable countries. Over the last decade there have been various local programs integrating pharmacists in general practice across Australia. This article summarises the results of an evaluation in Canberra from 2016–2021. Pharmacists predominantly conducted clinical activities, including medication reviews and clinical audits. General practitioner (GP) acceptance and implementation of medication review recommendations was high (75%). General practice pharmacists were able to achieve positive clinical outcomes in asthma and smoking cessation. Surveys and interviews identified that the general practice pharmacist role was welcomed by patients, GPs, and other healthcare professionals. Patient satisfaction was very high, with patients supporting the expansion of this pharmacy service. Collaboration between the pharmacists and other healthcare professionals was high. Some pharmacists left employment in general practice after less than a year. Introducing a clear job description could be beneficial in retaining pharmacists, improving trust and working relationships, and enhancing collaboration. The majority of clinical activities conducted by the pharmacists had the potential to improve patient care and decrease healthcare costs. Apart from healthcare savings, benefit–cost ratios of income generated and costs reduced by pharmacists when compared to salaries suggested that pharmacists may be cost-beneficial in some scenarios. Absence of funding for this model of care remains a barrier to wider adoption in Australia and needs addressing. This study was approved by the University of Canberra Human Research Ethics Committee (Project number: 15–235) and funded under the Primary Health Network Program (Grant number: 25097479).</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"271-281"},"PeriodicalIF":2.1,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1878","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134803487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of local guideline introduction on surgical antimicrobial prophylaxis prescribing for open reduction internal fixations at an Australian tertiary hospital","authors":"Sarah Hassan BPharm (Hons), PhD,&nbsp;Vincent Chan BSc (Hons), BPharm, MPH, PhD, GradCertAcadPrac, AACPA,&nbsp;Julie E. Stevens BSc, BPharm (Hons), PhD,&nbsp;Ieva Stupans BPharm (Hons), PhD,&nbsp;Juliette Gentle MBBS, FRACS (Orth)","doi":"10.1002/jppr.1886","DOIUrl":"10.1002/jppr.1886","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Guidelines advocate for the use of single-dose prophylaxis in open reduction internal fixation (ORIF) procedures. The presence of local (institutional) guidelines may assist in the uptake of evidence-based recommendations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To determine the impact of local guideline introduction on prescribing practice for ORIF procedures at a metropolitan hospital in relation to our previous audit investigating adherence to national guidelines, which found that only 20.4% of ORIF patients received single-dose prophylaxis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>Antibiotic prescribing was audited for patients undergoing ORIF of closed fractures from July–December 2021 at a metropolitan, tertiary hospital following guideline introduction in April 2021. Data on perioperative prescribing regimens were collected, with results compared to recommendations in local guidelines. Descriptive statistics, chi-squared test, and Fisher's exact test were used to report categorical variables. Ethics approval was granted by Northern Health Office of Research, Ethics, and Governance (Reference no: NLR 72459) and registered with the RMIT University College Human Ethics Advisory Network (Reference no: RM 24642).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data were collected for 165 patients. Almost all patients (93.5%) received cefazolin preoperatively as per guidelines. Only 22.6% of patients received single-dose prophylaxis as per local guideline recommendations, with overall adherence to guidelines only 16.4%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Little change was observed in the proportion of patients who received single-dose prophylaxis as compared to our previous audit. There is a need to understand why guidelines are not adhered to despite the availability of national and local guidelines. An evaluation of local barriers may assist with informing future implementation strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"54 1","pages":"33-40"},"PeriodicalIF":2.1,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1886","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135696303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of thyroid disorders in older people","authors":"Gauri Godbole BPharm, MClinPharm, BCGP, AdvPP(II), AcSHP, CDP, FSHP,&nbsp;Tripti Joshi MBBS, MD, MPH, FRACP, MPhil,&nbsp;Monica Majumder BMed, BSc(Med)Hons","doi":"10.1002/jppr.1883","DOIUrl":"https://doi.org/10.1002/jppr.1883","url":null,"abstract":"<p>Thyroid disorders are common in older people and cause significant morbidity. There may be fewer symptoms at presentation and increased susceptibility to adverse events, making diagnosis and management more challenging. The approach to management of thyroid disorders in older people differs from that for younger individuals. Factors that need to be considered include frailty, concurrent illness, polypharmacy, drug–drug interactions, and target organ sensitivity to treatment. This review discusses the clinical presentation, pathophysiology, and management of thyroid disorders and the effects of medications on thyroid function in older people.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"291-297"},"PeriodicalIF":2.1,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1883","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134802237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and efficacy comparisons of intravenous trastuzumab biosimilars to the reference product medicine in treatment-naïve and switch-over patients with breast cancer: a systematic and meta-analysis","authors":"Nina K. Song BPharm (Hons),&nbsp;Hala Musa BSc (Hons), MSc, MPharm,&nbsp;Michael Soriano BS Pharmacy (PH),&nbsp;Mellissa Batger BSc, MPharm,&nbsp;Bryson Hawkins BPharm (Hons),&nbsp;Iqbal Ramzan Dip Pharmacy (NZ), MSc, PhD,&nbsp;David E. Hibbs BSc (Hons), PhD, Grad Cert Ed (Higher Ed),&nbsp;Jennifer Ong BPharm (Hons), PhD, Grad Cert Ed Studies (Higher Ed)","doi":"10.1002/jppr.1882","DOIUrl":"10.1002/jppr.1882","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Aim&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To compare the efficacy and safety of trastuzumab biosimilars to reference trastuzumab in patients with breast cancer. Trastuzumab, a biologic pharmaceutical product, has improved survival in hormone-oestrogen receptor 2 positive breast cancer. However, due to its high economic burden, ‘highly similar’ products known as biosimilars have been developed. Yet, concerns remain around the equivalency of efficacy and safety between biosimilars and their reference biologic.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Data Sources&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A systematic review with meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE, EMBASE, and Cochrane Central databases were searched from inception to 26 April 2021 to obtain all randomised control trial data reporting on safety and efficacy outcomes of patients with breast cancer treated with trastuzumab biosimilars.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Study Selection&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Studies were required to investigate and report on the safety and/or efficacy of trastuzumab. No restrictions were placed on study setting or intervention type and any study which reported at least one efficacy or safety outcome was included. A head-to-head comparison between the biosimilar and its reference biologic was not required for inclusion in the results. Only studies using randomised control trials were included. There was no restriction on the language the study was published in, and all abstracts, raw clinical trial data, and full-text studies were eligible.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Forty-one studies were identified to report on patients treated with trastuzumab. The odds of achieving an overall response rate in patients treated with a trastuzumab biosimilar compared to the reference over at least 24 weeks of treatment was 1.10 (95% confidence interval [CI] 0.94–1.29). The proportion of patients experiencing any treatment emergent adverse events were comparable between the two study arms, 1.07 (95% CI 0.87–1.32). The switching group contained one study with 342 patients in the meta-analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Trastuzumab biosimilars have comparable efficacy and safety to reference trastuzumab in treatment-naïve patients. However, evidence is lacking for switching patients from reference trastuzumab to biosimilars, so further work is required in the switch-over population.&lt;/p&gt;\u0000 ","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"54 1","pages":"1-32"},"PeriodicalIF":2.1,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1882","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135538829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study investigating the management, risk factors, and outcomes of patients diagnosed with Clostridioides difficile infection","authors":"Mitt M. Vongphakdi BPharm(Hons),&nbsp;Nicholas Ah Yui BPharm, GCClinPharm,&nbsp;Kevin OCallaghan MB BCh BAO, MPHTM, FRACP","doi":"10.1002/jppr.1881","DOIUrl":"https://doi.org/10.1002/jppr.1881","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The rate of <i>clostridioides difficile</i> infection (CDI) in Australia has increased by more than 8% between 2016–2018. This can be attributed to multiple factors including an ageing population, widespread antibiotic and proton-pump-inhibitor usage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>The aim of this study was to investigate the management, risk factors and outcomes for CDI to identify strategies to reduce its incidence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Method</h3>\u0000 \u0000 <p>A single-centre retrospective audit was completed using medical records for patients admitted to a 250-bed regional Queensland hospital with CDI in 2020–2021. Data surrounding CDI management for each patient was analysed against the Therapeutic Guidelines. This study was approved by The Prince Charles Hospital Human Research Ethics Committee (Reference No: LNR/HREC/QPCH/81287).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 72 cases with CDI during the study timeframe. Recent antibiotic prescription, proton-pump-inhibitor (PPI) use and antibiotic allergy labels were common. Thirty-five per cent of cases were treated appropriately. Eight per cent died, and nine per cent had relapsed CDI within 12 weeks of diagnosis. Common gaps found in the results included inappropriate selection of antibiotics based on the severity of disease and lack of documentation surrounding CDI cases left untreated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There are multiple opportunities for pharmacists to improve the care of patients with CDI which range from promoting guideline adherence, influencing prescriber antibiotic selection based on disease severity, prompting review of PPIs upon CDI diagnosis and prompting provider follow-up of CDI laboratory results pending at the point of patient discharge. The results of this study have prompted antimicrobial stewardship service review of all CDI admissions at the study site and indicates the need for a larger multiple-site study to raise awareness of CDI risk factors and severity criteria.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"262-267"},"PeriodicalIF":2.1,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134805527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selecting performance indicators for hospital pharmacy practice: A Canadian initiative","authors":"France Boucher BPharm, MSc,&nbsp;Benoît Lemire BPharm, MSc,&nbsp;Sylvie Schryve BArch, DEA,&nbsp;Linda Vaillant BPharm, MSc, MBA, FCSHP","doi":"10.1002/jppr.1880","DOIUrl":"10.1002/jppr.1880","url":null,"abstract":"<p>Activity-based funding is a method of funding hospitals according to the type and volume of services provided and adjusted to their patient population. Currently, pharmacy practice is mainly evaluated with costs and volumes, which are insufficient to properly measure the contribution of pharmacists. Facing the province of Quebec statewide implementation of activity-based funding, expert committees were set up to develop a set of indicators using a predefined framework to assess pharmacy performance throughout all hospital activities and patient care. Through consultations, partners and stakeholders showed strong support for the initiative, putting more emphasis on the assessment of appropriateness as well as quality and safety. Among the different roles of pharmacists, respondents favoured the assessment of the pharmaceutical care and education of trainees and colleagues. Of the 150 candidate indicators initially identified, 24 were selected, of which 13 were prioritised for experimentation.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"53 5","pages":"282-290"},"PeriodicalIF":2.1,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1880","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45881217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}